Ectrims actrims

Scientific Programme
Wednesday, 25 October 2017
Teaching Courses, Hall C
08:30 - 10:00 Teaching Course 1: Disease modifying treatment
Chairs
R.J. Fox (Cleveland, US)
L. Kappos (Basel, CH)
08:30 - 09:00 DMTs 2017: new MS treatments and updates on established treatments
09:00 - 09:30 Defining what is working: choosing when and how to escalate therapy
09:30 - 10:00 Clinical trial statistics: pearls and lessons from MS trials
M.P. Sormani (Genoa, IT)
Teaching Courses, Hall D
08:30 - 10:00 Teaching Course 2: MS and reproduction: from
contraception to post conception reproductive
epidemiology and planning a pregnancy in women with MS
Chairs
K. Hellwig (Bochum, DE)
A. Langer Gould (Pasadena, US)
08:30 - 09:00 Counselling of women with MS in the reproductive age – from
contraception to conception-general recommendations
M.K. Houtchens (Brookline, US)
09:00 - 09:30 Multiple sclerosis and pregnancy management in 2017: medications and
lactation
09:30 - 10:00 Reproductive epidemiology in multiple sclerosis (puberty, pregnancy,
breastfeeding, assisted reproductive techniques and menopause)
Teaching Courses, Hall E
08:30 - 10:00 Teaching Course 5: Biomarkers in MS
Chairs
B. Hemmer (Munich, DE)
M. Comabella (Barcelona, ES)
Page 1 / 108

08:30 - 09:00 General considerations to develop and use biomarkers in MS
B. Hemmer (Munich, DE)
09:00 - 09:30 Biomarkers of neuroinflammation
09:30 - 10:00 Biomarkers of CNS neurodegeneration
M. Otto (Ulm, DE)
Teaching Courses, Hall F
08:30 - 10:00 Teaching Course 4: Myelin repair: scientific background
and clinical implications
Chairs
B. Stankoff (Paris, FR)
L. Leocani (Milan, IT)
08:30 - 09:00 Mechanisms leading to success or failure of myelin repair in the central
nervous system
R. Franklin (Cambridge, UK)
09:00 - 09:30 Evaluation of myelin repair: electrophysiological outcomes
09:30 - 10:00 Evaluation of myelin repair: imaging outcomes
B. Stankoff (Paris, FR)
Teaching Courses, Hall G
08:30 - 10:00 Teaching Course 3: Advanced MS genetics and
immunology
Chairs
R. Liblau (Toulouse, FR)
F. Zipp (Mainz, DE)
08:30 - 09:00 The MS genomic map: translating genetic architecture into a roadmap for
dissecting neuroimmune mechanisms
P. De Jager (New York, US)
09:00 - 09:30 Immunology of MS: how does the pathogenic adaptive immune response
develop?
R. Liblau (Toulouse, FR)
09:30 - 10:00 Immunology of MS: innate and adaptive immune events within the CNS
F. Zipp (Mainz, DE)
Page 2 / 108

10:30 - 12:00 Teaching Course 6: Controversy in management
Chairs
A.E. Miller (New York, US)
X. Montalban (Barcelona, ES)
10:30 - 11:00 Case 1: relapsing MS
A.E. Miller (New York, US)
11:00 - 11:30 Case 2: progressive MS
11:30 - 12:00 Case 3: neuromyelitis optica spectrum disorder (NMOSD)
I. Katz Sand (New York, US)
10:30 - 12:00 Teaching Course 7: Symptomatic therapy of gait
disturbances, spasticity, bladder dysfunction and
paroxysmal symptoms
Chairs
T. Berger (Innsbruck, AT)
M. Pakzad (London, UK)
10:30 - 11:00 Bladder dysfunction: pitfalls and challenges
M. Pakzad (London, UK)
11:00 - 11:30 Spasticity and walking impairment: early to recognise and to treat
C. Oreja-Guevara (Madrid, ES)
11:30 - 12:00 Paroxysmal symptoms: often neglected, but treatment needed
T. Berger (Innsbruck, AT)
10:30 - 12:00 Teaching Course 8: Brain atrophy in clinical practice:
evidence base and barriers to implementation
Chairs
F. Barkhof (Amsterdam, NL)
J. Sastre-Garriga (Barcelona, ES)
10:30 - 11:00 Natural history & clinical relevance of brain volume changes in patients
with MS
11:00 - 11:30 Value of brain volume changes to predict treatment response in patients
with MS
Page 3 / 108

11:30 - 12:00 Barriers to brain volume measurement in the real world
M. Battaglini (Siena, IT)
10:30 - 12:00 Teaching Course 9: Cognition
Chairs
M.P. Amato (Florence, IT)
J. DeLuca (New Orange, US)
10:30 - 11:00 Epidemiology of cognitive impairment: an update
M.P. Amato (Florence, IT)
11:00 - 11:30 Current approaches to management
J. DeLuca (New Orange, US)
11:30 - 12:00 Cognition as a clinical outcome measure in clinical trials on DMDs
R.H. Benedict (Buffalo, US)
Teaching Courses, Hall G
10:30 - 12:00 Teaching Course 10: Progressive multiple sclerosis and
the relationship to relapsing disease - how neuroglial inter-
actions underlie the pathogenesis and treatment
Chairs
S. Ludwin (Kingston, CA)
H. Lassmann (Wien, AT)
10:30 - 11:00 Oxidative injury to glial cells and neurons as a basis for progressive
disease
11:00 - 11:30 Astrocyte patho-biology and interactions with other glia and neurons in
the development of PMS
S. Ludwin (Kingston, CA)
11:30 - 12:00 Targeting glia as the basis of treating progressive PMS
V.W.W. Yong (Calgary, CA)
Satellite Symposia, Hall B
12:30 - 13:30 European Charcot Foundation - Reconsidering the concept
of induction therapy
Chairs
G. Comi (Milan, IT)
Page 4 / 108

12:30 - 12:50 The concept
M.S. Freedman (Ottawa, CA)
12:50 - 13:10 The evidence
G. Edan (Rennes, FR)
13:10 - 13:30 The problems and the future perspectives
H.-P. Hartung (Duesseldorf, DE)
12:30 - 14:00 Teaching Course 11: Differential diagnoses
Chairs
S. Fredrikson (Stockholm, SE)
A. Siva (Istanbul, TR)
12:30 - 13:00 Diagnostic and differential diagnostic dilemmas in MS
S. Fredrikson (Stockholm, SE)
13:00 - 13:30 MRI-diagnostic possibilities and pitfalls
A. Siva (Istanbul, TR)
13:30 - 14:00 NMOSD including antiMOG related disorders as differential diagnoses to
MS
B. Weinshenker (Rochester, US)
12:30 - 14:00 Teaching Course 12: Neuromyelitis optica spectrum
disorders
Chairs
D.M. Wingerchuk (Scottsdale, US)
K. Fujihara (Sendai, JP)
12:30 - 13:00 Update on pathogenesis of NMOSD
K. Fujihara (Sendai, JP)
13:00 - 13:30 Diagnostic issues with AQP4-IgG-seropositive and -seronegative NMOSD
D.M. Wingerchuk (Scottsdale, US)
13:30 - 14:00 Optimising treatment of NMOSD in various situations
R. Marignier (Lyon, FR)
Page 5 / 108

12:30 - 14:00 Teaching Course 13: Imaging the non-MS lesion in MS
Chairs
D. Reich (Bethesda, US)
A. Rovira (Barcelona, ES)
12:30 - 13:00 Atypical imaging presentations of MS and other idiopathic demyelinating
diseases
13:00 - 13:30 Imaging the complications of MS therapies
D. Reich (Bethesda, US)
13:30 - 14:00 The central vein sign on MRI
P. Sati (Bethesda, US)
12:30 - 14:00 Teaching Course 14: OCT in clinical practice
Chairs
S. Galetta (New York, US)
L. Balcer (New York, US)
12:30 - 13:00 OCT in MS: what have we learned so far?
L. Balcer (New York, US)
13:00 - 13:30 OCT in MS: what is new?
S. Saidha (Baltimore, US)
13:30 - 14:00 OCT in the clinic: case by case
S. Galetta (New York, US)
Teaching Courses, Meeting Room 315
12:30 - 14:00 Case-based Teaching Course 15: Paediatric MS
Chairs
B. Banwell (Philadelphia, US)
K. Deiva (Paris, FR)
12:30 - 13:15 Case presentation 1
B. Banwell (Philadelphia, US)
K. Deiva (Paris, FR)
Page 6 / 108

Parallel Sessions, Hall B
14:00 - 15:30 Parallel Session 1: Prevalence and phenotype evolution of
MS in different continents
Chairs
P. Duquette (Montréal, CA)
M.A.A. Sahraian (Tehran, IR)
14:00 - 14:20 Asia
Y. Takashi (Tokyo, JP)
14:20 - 14:40 Africa-Middle East
R. Gouider (Manouba, TN)
14:40 - 15:00 Latin America
L. Negrotto (Buenos Aires, AR)
15:00 - 15:20 Australia and New Zealand
H. Butzkueven (Melbourne, AU)
15:20 - 15:30 The clinical course, therapeutic responses, and outcomes in relapsing
MOG antibody-associated demyelination
S. Ramanathan (Sydney, AU)
Young Scientific Investigators’ Sessions, Hall C
14:00 - 15:30 Young Scientific Investigators' Session 1
Chairs
P. Calabresi (Baltimore, US)
V. Zujovic (Paris, FR)
14:00 - 14:15 Brain atrophy rates in multiple sclerosis changes along disease course
are sensitive to image processing method: not ready for NEDA-4 yet?
M. Andorrà (Barcelona, ES)
14:15 - 14:30 Altered default-mode network dynamics in cognitively impaired MS
patients
A.J. Eijlers (Amsterdam, NL)
14:30 - 14:45 Ganglion cell layer atrophy starts one week after onset of acute optic
neuritis and progress over 18 months
E.H. Martinez-Lapiscina (Barcelona, ES)
14:45 - 15:00 Predicting performance improvements with visuomotor training in MS
using a multi-modal clinical and neuroimaging approach
I. Lipp (Cardiff, UK)
15:00 - 15:15 Enlargement of white matter MS lesions is associated with lesional
microglial activation measured in vivo
C. Benoit (Paris, FR)
Page 7 / 108

15:15 - 15:30 Independent contributions of cervical cord lesions and thalamic,
cerebellar, and putaminal volumes to upper extremity function in early
multiple sclerosis
A. Harel (New York, US)
Nurses Sessions, Hall E
14:15 - 15:30 Nurses' Session 1: Impact of MS nursing across Europe
Chairs
A. Winslow (Dublin, IE)
14:15 - 14:25 Introduction and welcome
D. Miller (London, UK)
A. Winslow (Dublin, IE)
14:25 - 14:40 MS Nurse Pro – Launch of the rehabilitation module
N. Abel (Birmingham, UK)
14:40 - 15:30 Core challenges, opportunities and impact of MS nursing across Europe
(panel-debate)
A. Perrin Ross (Maywood, US)
V. Matthews (Herts, UK)
K. Harrison (Blaricum, NL)
R. Motta (Genoa, IT)
M. Skrzypek (Gdansk, PL)
J. Hlavacova (Prague, CZ)
Teaching Courses, Meeting Room 315
14:15 - 15:45 Case-based Teaching Course 16: Induction treatment in
very active multiple sclerosis: why, how, when?
Chairs
E. Le Page (Rennes, FR)
E. Le Page (Rennes, FR)
Page 8 / 108

Teaching Courses, Meeting Room 313/314
14:15 - 15:45 Case-based Teaching Course 17: Definition of non-
responders
Chairs
M. Tintoré (Barcelona, ES)
A. Ruet (Bordeaux, FR)
14:15 - 15:00 Case presentation 1: failing to first line treatment: NEDA vs MEDA
A. Ruet (Bordeaux, FR)
15:00 - 15:45 Case presentation 2: definition on treatment response in second line
treatment: how to face pregnancy desire while being on treatment
Teaching Courses, Meeting Room 311/312
14:15 - 15:45 Case-based Teaching Course 18: Progressive MS: whom to
treat, with what and for how long?
Chairs
B.A. Cree (San Francisco, US)
F. Paul (Berlin, DE)
14:15 - 15:00 Progressive MS: whom to treat, with what and for how long?
Hot Topic Sessions, Hall B
16:00 - 16:45 Hot Topic 1: Progressive MS alliance: what’s new
Chairs
W.M. Carroll (Nedlands, AU)
A.J. Thompson (London, UK)
16:00 - 16:15 Selected project
D.L. Arnold (Montréal, CA)
16:15 - 16:30 Bioinformatics and cell reprogramming to develop an in vitro platform to
discover new drugs for progressive multiple sclerosis (BRAVEinMS)
G. Martino (Milan, IT)
16:30 - 16:45 Development of a drug discovery pipeline for secondary progressive MS
F.J. Quintana (Boston, US)
Page 9 / 108

Young Scientific Investigators’ Sessions, Hall C
16:00 - 17:15 Young Scientific Investigators' Session 2
Chairs
S. Zamvil (San Francisco, US)
16:00 - 16:15 Loss of tolerance of thyroid-specific B cells as a biomarker for increased
risk for AITD in anti-CD52 treated MS patients
M.J. Smith (Aurora, US)
16:15 - 16:30 Propionic acid modulates T effector cell balance and function in MS
patients
A. Duscha (Bochum, DE)
16:30 - 16:45 Proposed NASSC classification criteria provide labels for patients with
early Susac syndrome but do not meet EuSaC diagnostic criteria
G.R. Paton (Vancouver, CA)
16:45 - 17:00 Different patterns of structural and microstructural damage in
Neuromyelitis Optica Spectrum Disorders
A. d'Ambrosio (Milan, IT)
17:00 - 17:15 Monitoring treatment response in MS by serum NFL reflect treatment
efficacy
L. Novakova (Gothenburg, SE)
Hot Topic Sessions, Hall D
16:00 - 16:45 Hot Topic 2: e-MS and patients related outcomes
Chairs
M. Trojano (Bari, IT)
P.A. Gourraud (San Francisco, US)
16:00 - 16:15 Interests and needs of health intervention technology in chronic diseases
T. Ziemssen (Dresden, DE)
16:15 - 16:30 Utilizing mobile technology in the assessment and monitoring of MS
patients
J. Alberts (Cleveland, US)
16:30 - 16:45 Pros and cons of web based outcomes measures to monitor disease
progression
G. Giovannoni (London, UK)
Page 10 / 108

Nurses Sessions, Hall E
16:00 - 17:15 Nurses' Session 2: Nurses leading the translation of
research into practice
Chairs
A.K. Krakau Hansen (Copenhagen, DK)
N. Barker (London, UK)
16:00 - 16:25 Adolescents’ experiences on coping with parental multiple sclerosis
T. Mauseth (Bergen, NO)
16:25 - 16:50 A nurses guide to MS brain health: practical strategies for implementing
MS brain health into everyday clinical practice
J. Haartsen (Melbourne, AU)
16:50 - 17:15 A comprehensive approach to meeting the needs and demands of people
with multiple sclerosis. Translational results of an ECTRIMS Nurse MS
Fellowship
M.A. Robles Sanchez (Barcelona, ES)
Satellite Symposia, Hall A
17:30 - 18:30 Satellite Symposium - Navigating choice. Can real world
evidence (RWE) deliver personalised medicine?
Supported by Biogen International
Chairs
S. Vukusic (Lyon, FR)
17:30 - 18:30 Interactive Session
S. Braune (Prien, DE)
J. Hillert (Stockholm, SE)
T. Kalincik (Melbourne, AU)
Satellite Symposia, Hall A
18:45 - 19:45 Satellite Symposium - Understanding neuropreservation:
how does it translate to clinical outcomes?
Supported by Sanofi Genzyme
Chairs
18:45 - 18:50 Introduction
18:50 - 19:15 How is neuropreservation in MS evaluated?
Page 11 / 108

19:15 - 19:40 Preserving brain and improving clinical outcomes: how are they related?
A. Traboulsee (Vancouver, CA)
19:40 - 19:45 Close
Page 12 / 108

Thursday, 26 October 2017
Satellite Symposia, Hall D
07:45 - 08:45 Satellite Symposium - New horizons in progressive
multiple sclerosis
Supported by MedDay Pharmaceuticals
Chairs
J. Antel (Montreal, CA)
D.J. Mahad (Edinburgh, UK)
07:45 - 08:00 New classification and challenges in progressive MS
08:00 - 08:10 Update on mechanisms involved in neuronal degeneration
M. Kerschensteiner (Munich, DE)
08:10 - 08:20 Innovation in progressive MS: the metabolic approach
O. Gout (Paris, FR)
08:20 - 08:30 Rehabilitation in progressive MS: from evaluation to treatment
M. Haupts (Isselburg-Anholt, DE)
08:30 - 08:45 Q&A and closure of the meeting
Plenary Sessions, Hall A
09:00 - 10:15 Plenary Session 1 - Welcome and ECTRIMS-ACTRIMS
Opening Lecture
Chairs
J. Antel (Montreal, CA)
C. Lubetzki (Paris, FR)
09:00 - 09:30 Welcome to MSParis2017 incl. cultural feature
C. Lubetzki (Paris, FR)
V. Pecresse (Paris, FR)
09:30 - 10:15 ECTRIMS-ACTRIMS Opening Lecture: From neuropathology to new patho-
physiological concepts and clinical perspectives
Page 13 / 108

Parallel Sessions, Hall A
10:45 - 12:15 Parallel Session 2: The new MS criteria
Chairs
A.H. Cross (St. Louis, US)
S. Chandran (Edinburgh, UK)
10:45 - 11:05 2017 proposed revisions to the McDonald diagnostic criteria for multiple
sclerosis
J.A. Cohen (Cleveland, US)
11:05 - 11:25 Impact of the new criteria on disease management
J. Chataway (London, UK)
11:25 - 11:37 The added value of oligoclonal bands in the multiple sclerosis diagnostic
criteria
G. Arrambide (Barcelona, ES)
11:37 - 11:49 Revised McDonald 2010 versus MAGNIMS 2016 MRI criteria in CIS
patients suggestive of MS: a multicenter study
M. Filippi (Milano, IT)
11:49 - 12:01 Comparative evaluation of successive criteria for neuromyelitis optica
R. Marignier (Lyon, FR)
12:01 - 12:13 Impact of including optic nerve lesions in dissemination in space in
diagnostic criteria for multiple sclerosis
W.J. Brownlee (London, UK)
10:45 - 12:15 Parallel Session 3: Update on MS prognostic markers
Chairs
D. Brassat (Toulouse, FR)
C. Teunissen (Amsterdam, NL)
10:45 - 11:05 Prognostic biomarkers in multiple sclerosis
E. Thouvenot (Nîmes, FR)
11:05 - 11:25 Prognostic imaging markers of MS
C. Azevedo (Los Angeles, US)
11:25 - 11:37 New spinal cord and infratentorial lesions in early relapse-onset MS are
predictive of secondary progressive disease course after 15 years
11:37 - 11:49 Temporal variability profile of serum neurofilament light levels in
multiple sclerosis patients
P. Calabresi (Baltimore, US)
11:49 - 12:01 Association between psychiatric comorbidity and disability progression
of multiple sclerosis
K.A. McKay (Vancouver, CA)
Page 14 / 108

12:01 - 12:13 Structural MRI predictors of cognitive decline in MS
A.J. Eijlers (Amsterdam, NL)
Parallel Sessions, Hall C
10:45 - 12:15 Parallel Session 4: Axon/myelin injury in MS lesions and
experimental models
Chairs
M. Friese (Hamburg, FR)
P. Stys (Calgary, CA)
10:45 - 11:05 Immune mediated injury of axon-myelin unit
M. Simons (Göttingen, DE)
11:05 - 11:25 Evolution of the MS plaques
C. Lucchinetti (Rochester, US)
11:25 - 11:37 Connexins in neuromyelitis optica: a link between astrocytopathy and
demyelination
C. Richard (Lyon, FR)
11:37 - 11:49 Influx of extracellular calcium drives axonal degeneration in an animal
model of multiple sclerosis
M.E. Witte (Munich, DE)
11:49 - 12:01 The staging of astrocytopathy in neuromyelitis optica spectrum disorders
with aquaporin4-IgG
Y. Takai (Sendai, JP)
12:01 - 12:13 Evaluation of the neuroprotective properties of alpha-lipoic acid by
optical coherence tomography in a model of experimental autoimmune
encephalomyelitis-optic neuritis
P. Albrecht (Düsseldorf, DE)
Parallel Sessions, Hall D
10:45 - 12:15 Parallel Session 5: The blood brain barriers in MS
Chairs
K. Akassoglou (San Francisco, US)
P.-O. Couraud (Paris, FR)
10:45 - 11:05 The brain barriers control immune privilege of the CNS
B. Engelhardt (Berne, CH)
11:05 - 11:25 Blood brain barrier adhesion molecules as therapeutic targets in MS
A. Prat (Montreal, CA)
11:25 - 11:37 Integrin alpha8 is a novel mediator of proinflammatory T lymphocyte
migration across the CNS barriers
E.M. Gowing (Montreal, CA)
Page 15 / 108

11:37 - 11:49 Antigen expression by endothelial cells of the blood brain barrier elicits
activation and pathogenicity of CD8 T cells in the central nervous system
C. Meyer (Toulouse, FR)
11:49 - 12:01 EGFL7 is a novel player in multiple sclerosis that beneficially regulates
CNS infiltration
C. Larochelle (Montreal, CA)
12:01 - 12:13 Astrocytic tight junctions control inflammatory CNS lesion pathogenesis
C. Chapouly (New York, US)
Satellite Symposia, Hall B
12:45 - 13:45 Satellite Symposium - Beyond the lightbulb: exploring the
known unknown
Supported by Roche
12:45 - 12:50 Welcome and introduction
M. Duddy (Newcastle upon Tyne, UK)
12:50 - 13:05 Chronic features of MS pathology in image: from the tissue to MRI and
then back
13:05 - 13:20 From acute and chronic inflammation to disability outcomes?
S. Hauser (San Francisco, US)
13:20 - 13:35 Are we seeing but not recognising disease progression in clinical
practice?
D. Horakova (Prague, CZ)
13:35 - 13:45 Questions and answers session
M. Duddy (Newcastle upon Tyne, UK)
Satellite Symposia, Hall D
12:45 - 13:45 Satellite Symposium - Neuro-restoration in multiple
sclerosis: science fiction or reality?
Supported by AbbVie
Chairs
J. Kesselring (Valens, CH)
Page 16 / 108

12:45 - 13:00 How does the biology of neuro-restoration differ from disability
progression in MS?
13:00 - 13:15 Recent insights from progressive MS clinical trials: what will a
neurorestoration study look like?
13:15 - 13:30 Managing expectations of patients with progressive MS
J. Kesselring (Valens, CH)
13:30 - 13:45 Panel discussion
Parallel Sessions, Hall A
14:00 - 15:30 Parallel Session 6: Therapeutic perspectives in
progressive MS
Chairs
R. Kapoor (London, UK)
J.S. Wolinsky (Houston, US)
14:00 - 14:20 Prognostic factors in progressive MS
14:20 - 14:40 Therapeutic advances and failures in progressive MS
F. Lublin (New York, US)
14:40 - 14:52 The effect of disease-modifying treatments on conversion to secondary
progressive multiple sclerosis
J.W.L. Brown (Cambridge, UK)
14:52 - 15:04 Effects of siponimod on MRI outcomes in patients with secondary
progressive multiple sclerosis: results of the phase 3 EXPAND study
15:04 - 15:16 MD1003 in progressive multiple sclerosis: 24-month brain MRI results of
the MS-SPI trial
15:16 - 15:28 Natalizumab improves walking and upper-limb disability compared with
placebo in patients with secondary progressive multiple sclerosis: an
integrated, post hoc area under the outcome-time curve analysis from
the ASCEND trial
Page 17 / 108

14:00 - 15:30 Parallel Session 7: Paediatric MS
Chairs
A. Boyko (Moscow, RU)
M. Tardieu (Paris, FR)
14:00 - 14:20 Longterm prognosis of pediatric MS
R. Hintzen (Rotterdam, NL)
14:20 - 14:40 Treatment of pediatric MS
E. Waubant (San Francisco, US)
14:40 - 14:52 Regional grey matter atrophy in pediatric patients with multiple
sclerosis: a longitudinal MRI study
E. De Meo (Milan, IT)
14:52 - 15:04 Cognitive reserve is associated with better cognitive outcome and socio-
professional attainment in both adult and pediatric-onset multiple
sclerosis
L. Pasto' (Florence, IT)
15:04 - 15:16 Effect of age and gender on disease progression in pediatric multiple
sclerosis population
M. Gurevich (Ramat-Gan, IL)
15:16 - 15:28 Serial MRI detects presence and evolution of a 'surface-in' gradient of
thalamic damage in paediatric-onset MS, which is recapitulated in adult
MS autopsy
G. Fadda (Montreal, CA)
Parallel Sessions, Hall C
14:00 - 15:30 Parallel Session 8: Immune cells in injury and repair
Chairs
F. Zipp (Mainz, DE)
A. Bar-Or (Philadelphia, US)
14:00 - 14:20 New insight into immune related CNS injury
L. Steinman (Standford, US)
14:20 - 14:40 Immune checkpoint blockade in combating Alzheimer's disease
M. Schwartz (Rehovot, IS)
14:40 - 14:52 Adaptive immunity drives remyelination failure or success in multiple
sclerosis
C. Sanson (Paris, FR)
14:52 - 15:04 Patterns of microglia/macrophage polarization in multiple sclerosis and
stroke lesions
T. Zrzavy (Vienna, AT)
Page 18 / 108

15:04 - 15:16 Unexpected role of neutrophil granulocytes during both murine and
human central nervous system autoimmunity
B. Knier (München, DE)
15:16 - 15:28 B cell-mediated experimental CNS autoimmunity is modulated by
inhibition of Bruton's tyrosine kinase
S. Torke (Goettingen, DE)
Parallel Sessions, Hall D
14:00 - 15:30 Parallel Session 9: New insight into grey matter pathology
in MS
Chairs
C. Stadelmann (Göttingen, DE)
B. Trapp (Cleveland, US)
14:00 - 14:20 Synaptic pathology in cortex of multiple sclerosis
D. Merkler (Geneva, CH)
14:20 - 14:40 Connection between inflammation and cortical neuronal pathology in MS
and EAE
D. Centonze (Rome, IT)
14:40 - 14:52 The axon initial segment: a novel site of neuronal dysfunction in multiple
sclerosis
M. Davenne (Paris, FR)
14:52 - 15:04 Thalamic MRI and histopathologic correlations in advanced multiple
sclerosis
K. Mahajan (Cleveland, US)
15:04 - 15:16 Neural correlates of cognitive phenotypes in multiple sclerosis
V.M. Leavitt (New York, US)
15:16 - 15:28 Meningeal inflammation is linked to subpial cortical demyelination in
progressive multiple sclerosis with ongoing white matter pathology
V. Ramaglia (Toronto, CA)
Poster Sessions, Poster Exhibition
Poster Session 1
Diagnostic criteria for Susac syndrome
M. Ringelstein (Düsseldorf, DE)
Time influences the performance of diagnostic criteria for multiple sclerosis
Evaluation of the sensitivity of the 2016 MAGNIMS MRI criteria for dissemination in space in
children
Y. Hacohen (London, UK)
Page 19 / 108

Lesion topographies in the multiple sclerosis diagnostic criteria: a reappraisal
B. Arrambide (Barcelona, ES)
Brain and spinal cord imaging features in neuromyelitis optica spectrum disorder
L. Cacciaguerra (Milan, IT)
Performance of 2010 McDonald criteria and 2016 MAGNIMS guidelines in the diagnosis of
primary progressive multiple sclerosis
A. Gajofatto (Verona, IT)
Brain microglial activation detected by TSPO PET at the pre-symptomatic stage of MS
E. Poirion (Paris, FR)
Clinical and prognosis profile of paraneoplastic neuromyelitis optica spectrum disorders
N. Sola-Valls (Barcelona, ES)
Susac syndrome: clinical features, laboratory testing and treatment responses of 20 cases
C. Boz (Trabzon, TR)
Epidemiology of neuromyelitis optica spectrum disorders in Catalonia: a population-based
study
A. Saiz (Barcelona, ES)
Double seronegative longitudinally extensive transverse myelitis: preliminary study on 17
patients
E. Maillart (Paris, FR)
Immunoglobulin free light chains in saliva: a new marker of multiple sclerosis?
E. Ganelin-Cohen (Petach Tikva, IL)
Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a
cohort of Latin American patients: the impact on diagnostic rates
E.G. Carnero Contentti (Buenos Aires, AR)
A molecular-based approach using long, non-coding RNA and enhancer-associated lncRNA
gene expression signatures to classify multiple sclerosis using peripheral whole blood
C.F. Spurlock, III (Nashville, US)
New possibilities in multiple sclerosis imaging evaluation: studying the performance of
Phase Sensitive Inversion Recovery (PSIR) in juxtacortical lesions
M.C.A. Vecino (Porto Alegre, BR)
Myelin oligodendrocyte glycoprotein antibodies predict a favourable outcome in
neuromyelitis optica related disorders
A. Cobo-Calvo (Lyon, FR)
Myelin oligodendrocyte glycoprotein antibodies spectrum disorder: clinical features and
prognostic factors in a cohort of 150 adult patients
A. Cobo-Calvo (Lyon, FR)
Prognostic factor for therapeutic response of attacks in anti-AQP4, anti-MOG seropositive
and NMO seronegative patients
N. Collongues (Strasbourg, FR)
Page 20 / 108

Complement activation is associated with microscopic pathology in the placentas of women
with NMO
R. Bove (San Francisco, US)
Neuromyelitis optica spectrum disorders: 20 year single centre observational data with
treatment analysis
D.B. Bichuetti (Sao Paulo, BR)
Anti-MOG antibodies induce complement mediated demyelination in isolated optic neuritis
and myelitis
C. Tortorella (Bari, IT)
Ethnic differences in clinical manifestation and outcome of neuromyelitis optica spectrum
disorder
S.-H. Kim (Goyang, KR)
Clinical, MRI and laboratory features of myelin oligodendrocyte glycoprotein
(MOG)-antibody-associated neurologic disease: a study of 259 cases
K. Kaneko (Sendai, JP)
NMOSD relapses: an analysis of 328 episodes in 75 cases
S.A. Broadley (Griffith University, AU)
Multiple sclerosis AHI1 genetic risk promotes IFNg+ CD4+ T cells
W. Elyaman (New York, US)
Double inversion recovery MRI in the evaluation of the anterior visual pathway in patients
with multiple sclerosis and neuromyelitis optica spectrum disorders
E. Saji (Niigata, JP)
What could be the clinical and MRI spectrum of anti-MOG associated disorders?
V. Papp (Aarhus, DK)
Disease course and immunotherapies responses in children with relapsing myelin
oligodendrocyte glycoprotein antibodies (MOG-Ab)-associated disease
Y. Hacohen (London, UK)
Psychiatric morbidity develops after onset of pediatric multiple sclerosis: a Danish
nationwide population-based study
M.S. Boesen (Copenhagen, DK)
Childhood multiple sclerosis is associated with reduced brain volumes at disease onset and
brain growth failure
F. Bartels (Berlin, DE)
Executive dysfunction in paediatric-onset multiple sclerosis: deficits above and beyond
slowed processing speed
E. Barlow-Krelina (Toronto, CA)
Clinical significance of anti-MOG antibodies in the evaluation of children with a first
demyelinating episode: prospective Spanish national cohort
T. Armangue (Barcelona, ES)
Page 21 / 108

Implications of the international paediatric multiple sclerosis study group consensus criteria
for paediatric acute disseminated encephalomyelitis: a Danish nationwide population-based
study
Continuous accelerometry as a measure of physical activity impairment in paediatric-onset
multiple sclerosis subjects versus healthy controls
J.N. Brenton (Charlottesville, US)
Chitinase 3-like 1 and neurofilament light chain in the cerebrospinal fluid predict pediatric
acquired CNS demyelinating disease
Evaluation of teriflunomide in children and adolescents with relapsing MS: TERIKIDS phase
3 study design, enrolment update, and baseline data
T. Chitnis (Boston, US)
Risk of secondary progressive multiple sclerosis: a longitudinal study
Characteristics of radiologically isolated syndrome (RIS) national French cohort
C. Lebrun-Frenay (Nice, FR)
Predicting MS disease progression remains a significant challenge: results from advanced
statistical models of RCT placebo arms
M. Copetti (S. Giovanni Rotondo, IT)
Looking back: patients with “aggressive MS” (EDSS 6.0 at 10 years) in the Barcelona CIS
cohort
Miscarriage induces reactivation of inflammation in relapsing-remitting multiple sclerosis
D. Landi (Rome, IT)
How common is truly benign MS?
E.C. Tallantyre (Cardiff, UK)
Long term outcomes of neuromyelitis optica: a systematic literature review
Z. Nasr (Rochester, US)
Description of patients with benign multiple sclerosis in the treatment era
A. Bouley (Providence, US)
Cognitive impairment can help to predict long-term disease course in benign multiple
sclerosis patients: a 12 year follow-up study
L. Razzolini (Florence, IT)
Long-term treatment effect over disability progression in patients with relapsing multiple
sclerosis
B. Casanova Estruch (València, ES)
Increased incidence of psychiatric disorders five years before diagnosis in multiple sclerosis
R.A. Marrie (Winnipeg, CA)
Page 22 / 108

A large cohort study of physical and psychological impacts of smoking on PwMS via the UK
MS Register
J. Rodgers (Swansea, UK)
A nationwide survey of the influence of month of birth on the risk of developing multiple
sclerosis in Sweden and Iceland
O. Eliasdottir (Gothenburg, SE)
Observatoire Français de la Sclérose en Plaques (OFSEP): a powerful epidemiological tool
R. Casey (Lyon, FR)
The multiple sclerosis partners advancing technology and health solutions (MS PATHS)
patient cohort
E.M. Mowry (Baltimore, US)
Social networks in persons at risk for developing multiple sclerosis
P. De Jager (New York, US)
Decline in PPMS diagnosis? The German view
D. Ellenberger (Göttingen, DE)
Concussion in adolescence and multiple sclerosis risk
T. Olsson (Stockholm, SE)
Clinical characteristics and treatment patterns of relapsing-remitting multiple sclerosis
patients with high disease activity
T. Spelman (Parkville, AU)
Factors impacting mortality rates in a large French Canadian MS population: a review of 4
decades of data
M.-C. Rousseau (Laval, CA)
Understanding the timing of environmental exposures in the risk of MS
B. Taylor (Hobart, AU)
Determining the incidence of MS in a Swedish county - overcoming challenges in using
registry data
I. Boström (Linköping, SE)
The prevalence of multiple sclerosis in the United States: a population-based healthcare
database approach
M.T. Wallin (Washington, US)
A population-based assessment of “no evident disease activity” (NEDA) in multiple sclerosis
N.E. Parks (Rochester, US)
Use of the new oral disease-modifying therapies among the multiple sclerosis population in
British Columbia, Canada over a five-year period (2011 - 2015)
S. Setayeshgar (Vancouver, CA)
Incidence and follow-up of acquired demyelinating syndromes in Dutch children - update of
a nationwide and prospective study
C.L. de Mol (Rotterdam, NL)
Page 23 / 108

The association between disease activity and disability progression in patients with
relapsing-remitting multiple sclerosis
Sex related differences of fetal maternal cross-talk modify phenotypic characteristics in
women with multiple sclerosis
P. Ragonese (Palermo, IT)
Harnessing electronic medical records to advance research on multiple sclerosis
V. Damotte (San Francisco, US)
Comparison of case-mix in multiple sclerosis patients participating in randomized control
trials, prospective observational studies, and multiple sclerosis partners advancing
technology and health solutions (MS PATHS)
F. Pellegrini (Zug, CH)
Assisted reproductive technologies and relapse risk: a new case series and pooled analysis
of existing studies
Pregnancy incidence and therapy exposure in relapsing forms of MS: a 12-year
retrospective multicentre analysis
V.G. Jokubaitis (Parkville, AU)
Alemtuzumab and pregnancy - a case series from the German MS and Pregnancy Registry -
X chromosome wide association analysis identified a novel FRMPD4 locus that differentially
effects MS risk by sex
Y. Zhou (Hobart, AU)
Infertility diagnosis and treatment in women with and without multiple sclerosis
M.K. Houtchens (Brookline, US)
Neonatal and delivery outcomes of babies to mothers with multiple sclerosis in Sweden
K. Fink (Solna, SE)
Unplanned pregnancy risk in a United States multiple sclerosis patient cohort
A.L. Smith (Cleveland, US)
Randomized controlled trial of two group programs in multiple sclerosis: 12-month (long-
term) follow-up effects on fatigue and self-efficacy
C. Hugos (Portland, US)
Abdominal massage in the self-management of constipation in people with multiple
sclerosis
D. McClurg (Glasgow, UK)
Perceived cognitive function in people with MS and its relationship to objective
neuropsychological measurement with BICAMS
N. McNicholas (Dublin, IE)
Cognitive impairment and brain atrophy in multiple sclerosis: a 10-year follow-up study
C.O. Jacobsen (Stavanger, NO)
Page 24 / 108

Factors that affect computerized cognitive screening in people with MS: diurnal variation,
location and practice effects
D. Merlo (Melbourne, AU)
Fatigue acceptance mediates cross-sectional and longitudinal associations between fatigue
and sleep disturbance in multiple sclerosis
A.J. Hughes (Baltimore, US)
Self-reported sleep disturbance and cognitive function in MS: mediating effects of
depressed mood and fatigue
A.J. Hughes (Baltimore, US)
Repeatability and validity of neurophysiological correlates of fatigue in people with multiple
sclerosis
P.M. Ellison (Newcastle Upon Tyne, UK)
Depressive symptoms are associated with more negative functional outcomes than anxiety
symptoms in persons with multiple sclerosis
S.A. Morrow (London, CA)
Neuroradiological characterization of multiple sclerosis patients with chronic pain
D. Plantone (Rome, IT)
Objective speech marker correlates with clinical scores in non-dysarthric MS
G. Noffs (Melbourne, AU)
Cognitive flexibility in multiple sclerosis patients may be dependent on information
processing speed
K. Zebenholzer (Vienna, AT)
Association between self-reported upper limb, lower limb and cognitive functioning and
functional performance in MS PATHS (multiple sclerosis partners advancing technology and
health solutions) patients
D. Miller (Cleveland, US)
Factors associated with fatigue in the NARCOMS registry
A. Salter (St. Louis, US)
Factors driving social withdrawal across multiple sclerosis disease types
R.J. Mills (Preston, UK)
The Expanded Timed Get Up and Go is a more sensitive predictor of disability than the
Timed 25-foot walk in people with multiple sclerosis
B. Weinstock-Guttman (Buffalo, US)
Intensive neurorehabilitation is associated with improved gait kinematic analysis in
C. Zanetta (Milano, IT)
Can we trust self-reported walking distance when determining EDSS scores? - A part of the
Danish MS Hospitals Rehabilitation Study
A.G. Skjerbaek (Ry, Haslev, DK)
Page 25 / 108

Continuous wrist-worn accelerometry captures change in average daily step count in people
with multiple sclerosis over one year
V.J. Block (San Francisco, US)
Convergent validity of acceleration-derived parameters from iPad®-based walking and
balance testing
F. Bethoux (Cleveland, US)
McArdle sign: a specific sign of multiple sclerosis
B. Weinshenker (Rochester, US)
How useful is the Hospital Anxiety and Depression Scale (HADS) in multiple sclerosis?
V.P. Patel (Toronto, CA)
Subclinical motor impairment assessed by an engineered glove correlates with MRI brain
damage in radiologically isolated syndromes
L. Bonzano (Genoa, IT)
Reliability and validity of a new, sensor-based system for gait analysis in patients with
multiple sclerosis
F. Flachenecker (Erlangen, DE)
Risk factors for cognitive impairment in multiple sclerosis as defined by the symbol digit
modalities test: a retrospective analysis of the University of Calgary Multiple Sclerosis Clinic
Database
T. Brust (Calgary, CA)
Fully automated detection, segmentation and quantification of mean cross-sectional area of
the spinal cord
F. Weiler (Bremen, DE)
Decreased articulation rate in multiple sclerosis and its relationship to overall disease
disability and cognitive function
B. Benova (Prague, CZ)
Phonatory dysfunction in multiple sclerosis
B. Benova (Prague, CZ)
Assessing upper extremity function and mobility with multiple clinical tests of the Assess
MS system
C.E. van Munster (Amsterdam, NL)
Disability measures used in multiple sclerosis patients: correlations with MRI-derived global
and microstructural damage
D. Jakimovski (Buffalo, US)
A Comparison of participant supplied EDSS scores and clinically submitted data via the UK
MS Register
R.M. Middleton (Swansea, UK)
Information processing speed on the SDMT is predicted by saccadic eye movement
dysfunction in patients with multiple sclerosis
N. Pawlak (New York, US)
Page 26 / 108

Validation of automated cortical and subcortical multiple sclerosis lesion detection using a
single 7T MP2RAGE scan
M.J. Fartaria (Lausanne, CH)
Validity of routine administration of Neuro-QoL in multiple sclerosis partners advancing
technology and health solutions (MS PATHS)
A. Boster (Columbus, US)
Reliability of BICAMS (Arabic version) in Egyptian multiple sclerosis patients
N. Kishk (Cairo, EG)
Timed up and go and brain atrophy: a preliminary MRI study to assess functional mobility
performance in multiple sclerosis
L. Lorefice (Cagliari, IT)
An investigation into the cognitive impact on physical disability in the community in people
with multiple sclerosis (PwMS)
M. Gudesblatt (Patchogue, US)
Health-related quality of life attributes associated with work productivity loss and caregiver
burden in multiple sclerosis
C. Hategeka (Vancouver, CA)
The burden of relapsing remitting multiple sclerosis on workers in the United States
J. Nicholas (Columbus, US)
Estimating MS-related work productivity loss and factors associated with labour force
participation in a representative Australian sample of people with multiple sclerosis
J. Chen (Hobart, AU)
Multiple sclerosis relapses: budget impact analysis of oral high-dose corticosteroids
D. Veillard (Rennes, FR)
The changing landscape of disease modifying treatments: cost implications for healthcare
systems
A. Zarkali (Canterbury, UK)
Pattern ERG related to ganglion cell loss and impaired visual function in patients multiple
sclerosis
H. Jiang (Miami, US)
Mapping focal loss of the ganglion cell-inner plexiform layer in patients multiple sclerosis
J. Wang (Miami, US)
Outer retinal function and structure in multiple sclerosis
J.V.M. Hanson (Zurich, CH)
Temporal dynamics of structural and functional retinal damage in acute optic neuritis
C.A. Wicki (Zurich, CH)
A new, sensitive visual test for the diagnosis of acute optic neuritis
G. Pihl-Jensen (Glostrup, DK)
Self-monitoring visual function via a smartphone application
N. Dubuisson (London, UK)
Page 27 / 108

The impact of depression and anxiety symptoms on information processing speed in MS and
other immune-mediated inflammatory diseases
C. Whitehouse (Halifax, CA)
Movement disorders in demyelinating diseases
C. Candeias da Silva (Sao Paulo, BR)
A change in multiple sclerosis morbidity spectrum
R. Hernández Clares (Murcia, ES)
Self-reported smoking status associated with clinical disease worsening in CombiRx
S.S. Cofield (Birmingham, US)
Neuropsychological impairment in newly diagnosed early multiple sclerosis: clinical and
neuropsychological characterization of a German cohort of 1124 patients
A. Salmen (Bochum, DE)
Altered grey matter networks in young patients with MS at genetic risk for Alzheimer's
disease
G. Gonzalez-Escamilla (Mainz, DE)
Prevalence of restless legs syndrome/Willis-Ekbom disease in multiple sclerosis: a case-
control study in Argentina
E.G. Carnero Contentti (Buenos Aires, AR)
Prevalence of sleep apnea in multiple sclerosis patients meeting clinical eligibility criteria
for the Sleep Apnea in Multiple Sclerosis Positive Airway Pressure (SAMSPAP) trial
S. Khadadah (Montreal, CA)
Excess of neurological and psychiatric comorbidity in multiple sclerosis patients as
compared to the general population in Catalonia, Spain
M.-A. Passarell (Barcelona, ES)
Blockade of MCAM on TH17 cells impedes their CNS infiltration over the choroid plexus
J. Breuer (Münster, DE)
Paraneoplastic neuromyelitis optica: an update on a single center cohort with cases of
histological validation
R. Carruthers (Vancouver, CA)
Inflammation effectively eliminates JC virus during progressive multifocal
leukoencephalopathy
L. Stork (Göttingen, DE)
Alterations of minicolumnar cytoarchitecture and axonal loss in multiple sclerosis cortex
M. Vercellino (Torino, IT)
The impact of high level of perivenular inflammation on active white matter lesions and
disease progression in multiple sclerosis
R. Magliozzi (Verona, IT)
Neuromyelitis optica: distinct staining patterns of sera containing AQP4- and MOG-
antibodies in the murine visual system
F. Graz (Bochum, DE)
Page 28 / 108

Focal cortical astrocytopathy lesions with demyelination and inflammatory cell infiltrates in
neuromyelitis optica spectrum disorder: a neuropathological study of eleven autopsied
cases
S. Hayashida (Fukuoka, JP)
In vivo modeling of the nascent multiple sclerosis lesion: epsilon toxin induced mechanisms
of blood brain barrier permeability
J.R. Linden (New York, US)
Focal overexpression of FGF9 in rat cortex induces de- and dysmyelination
C. Wrzos (Goettingen, DE)
Neutrophils mediate blood-brain barrier disruption in a rat model of neuromyelitis optica
A. Winkler (Göttingen, DE)
Critical role of GM-CSF, not IL-17, in relapsing experimental auto-immune encephalomyelitis
L. D'Auria (Chicago, US)
Subtle biochemical myelin pathology triggers secondary inflammatory demyelination in
mouse brain
A.V. Caprariello (Calgary, CA)
Visual evoked potentials reflect optic nerve demyelination in EAE
S. Marenna (Milan, IT)
Amelioration of secondary progressive experimental autoimmune encephalomyelitis by
restoring mitochondrial energy production in a GOT2-dependent manner
M. Kinoshita (Osaka, JP)
Immunomodulatory therapy in genetic mouse models of progressive multiple sclerosis
J. Groh (Wuerzburg, DE)
Transcriptomic analysis of disease reversal in EAE: comparison of laquinimod and FTY-720
J. Kaye (Netanya, IL)
Potential beneficial effect of neuroinflammation on experimental stroke
K. Guse (Bern, CH)
Optical coherence tomography identifies structural retinal damage in experimental
autoimmune encephalomyelitis
P. Manogaran (Zurich, CH)
Diffusion tensor imaging of the afferent visual pathway as an in vivo tool to assess
neurodegeneration in experimental autoimmune encephalomyelitis
C. Egger (Zurich, CH)
MicroRNA-146a deficiency protects against cuprizone-induced demyelination
Z. Illes (Odense, DK)
Investigating blood-brain barrier integrity, immune cell infiltration and disease-related
gender differences in a spontaneous transgenic mouse model for multiple sclerosis
C. Lachance (Montreal, CA)
Page 29 / 108

IL-15 enhances pro inflammatory T cell responses in multiple sclerosis and experimental
C. Laurent (Montreal, CA)
Preferential axonal accumulation of mitochondria during cuprizone-induced demyelination
S. Schmutz (Munich, DE)
Development of an in vitro myelination assay using mouse oligodendrocytes and a 3D
scaffold of engineered nanofibers
Y. Yang (Cleveland, US)
Effect of ozanimod (RPC1063) on action potential parameters in adult human Purkinje fibres
N. Abi-Gerges (San Diego, US)
Differential effects of primary and secondary progressive MS cerebrospinal fluid on motor
function and spinal cord pathology
J.K. Wong (New York, US)
NINJ2 as a novel protein involved in response to Interferon-β in multiple sclerosis
S. Peroni (Milan, IT)
An alternatively spliced isoform of HLA-DRA may be implicated in multiple sclerosis
V. Damotte (San Francisco, US)
Association of smoking but not HLA-DRB1*15:01, APOE, or body mass index with brain
atrophy in early multiple sclerosis
F. Luessi (Mainz, DE)
A whole-genome sequencing study associates GRAMD1B with multiple sclerosis risk and
disease activity
F. Martinelli Boneschi (Milan, IT)
Genotype is predicting multiple sclerosis lesion activity in autopsy cohort of the
Netherlands Brain Bank
N.L. Fransen (Amsterdam, NL)
Investigating the role of the major histocompatibility complex on multiple sclerosis in an
admixed Hispanic population
A. Beecham (Coral Gables, US)
A genetic risk variant for multiple sclerosis modulates the processing of CD58 mRNA and
microRNA-548ac from the same transcript
N. Boxberger (Rostock, DE)
Expression profile of long non-coding RNAs (lncRNAs) in serum of patients with progressive
multiple sclerosis
V. Nociti (Rome, IT)
An integrated candidate gene study of response to fingolimod in relapsing remitting
multiple sclerosis patients
F. Esposito (Milan, IT)
Understanding progression in multiple sclerosis through transcriptomics and DNA
methylation in CD4+ and CD8+ T cells
S. Fernandes (Solna, SE)
Page 30 / 108

DICAM: a new player in multiple sclerosis pathogenesis
C. Grasmuck (Montreal, CA)
Non-canonical autophagy drives CD4+ T cell reactivation during autoimmune CNS
inflammation
C.W. Keller (Zurich, CH)
The TH17-associated cytokine IL-26 enhances BBB integrity: implications for MS
E. Peelen (Montreal, CA)
CNS-transmigration of distinct B-cell subsets through the choroid plexus in patients with
multiple sclerosis
J. Haas (Heidelberg, DE)
Gene-expression analysis of blood memory CD8+T cells at the single-cell level reveals a
specific pattern of clonally expanded cells in multiple sclerosis patients
E. Dugast (Nantes, FR)
Microglia engulf invading living Th17 cells during neuroinflammation
B. Wasser (Mainz, DE)
Persistent clonally related CSF B cells in multiple sclerosis: a longitudinal immune
repertoire study
A.L. Greenfield (San Francisco, US)
The nuclear receptor Nur77 restricts T cell responses and limits central nervous system
autoimmunity
L. Klotz (Münster, DE)
Anti-MOG antibodies from NMO-SD patients facilitate low dose antigen recognition
promoting activation of peripheral auto-reactive T cells
S. Kinzel (Göttingen, DE)
Progressive multiple sclerosis: selective involvement of the CD30/CD153 signalling pathway
in innate immunity
R. Carruthers (Vancouver, CA)
Metabolic control of macrophage-mediated myelin phagocytosis: implications for multiple
sclerosis
Y.H. Lin (Montreal, CA)
Activation of the aryl hydrocarbon receptor in dendritic cells is sufficient for the UV-B-
induced amelioration of experimental autoimmune encephalomyelitis
N. Mykicki (Münster, DE)
Fingolimod-induced changes in the peripheral immune repertoire and their potential as
biomarkers of treatment response in multiple sclerosis
M. Ghadiri (Montreal, CA)
Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells
I. Smets (Leuven, BE)
Insulin and leptin impair regulatory T cell function in obese multiple sclerosis patients
J. Correale (Buenos Aires, AR)
Page 31 / 108

Histone deacetylase SIRT1 mediates C5b-9-induced cell cycle in oligodendrocytes
A. Tatomir (Baltimore, US)
CD70 expression defines a subset of pro-inflammatory and pathogenic T cells that are
implicated in multiple sclerosis
T. Dhaeze (Montréal, CA)
Amplified STAT phosphorylation signaling in peripheral blood mononuclear cells from MS
patients in response to interferon alpha
E. Canto (San Francisco, US)
Role of intestinal IgA-producing cells at regulating neuroinflammation in EAE
O. Rojas (Toronto, CA)
Single cell transcriptomics identifies multiple sclerosis-specific expression profiles of
cerebrospinal fluid cells
G. Meyer zu Hörste (Münster, DE)
Novel anti-neuronal antibodies in multiple sclerosis
J.D.E. Parratt (Sydney, AU)
Concerted T cell response in experimental autoimmune encephalomyelitis and multiple
sclerosis
N. Saligrama (Stanford, US)
A distinct repertoire of the γδ T cell population is associated with disease severity of
multiple sclerosis
K. Shinoda (Fukuoka, JP)
Inflammatory mediators regulate ARNT2 expression in CNS and peripheral immune
populations and influence their pathogenic or protective properties in MS and in models of
inflammatory neurodegeneration
J. Quandt (Vancouver, CA)
Cytotoxic CD4+CD28null T cell expansions are associated with worse disease progression in
patients with relapsing remitting multiple sclerosis
L.M. Peeters (Diepenbeek, BE)
Oxysterols impair IL-10 secretion and induces cholesterol accumulation in regulatory TR1
cells via LXR signalling to favour autoimmunity
C. Pot (Lausanne, CH)
PARP-1 deregulation in MS
M. Meira (Basel, CH)
Protein kinase CK2 controls CD4+ T-cell differentiation and is critical for pathogenicity in
autoimmune neuroinflammation
E. Benveniste (Birmingham, US)
The lysosomal K+ channel KCNK6 correlates with upregulated T cell autophagy in MS
patients
F. Steffen (Mainz, DE)
Intrathecal oligoclonal bands synthesis: is it always a prognostic factor?
J. Frau (Cagliari, IT)
Page 32 / 108

Gut-brain axis: deciphering the role of mucosal and systemic IgA in gut dysbiosis associated
with multiple sclerosis
A.-K. Pröbstel (San Francisco, US)
A bidirectional association between the gut microbiota and CNS disease in a progressive
bisphasic murine model of multiple sclerosis
L. Kasper (Hanover, US)
CD4+ T cells from multiple sclerosis patients acquire regulatory characteristics following
exposure to a gut commensal-derived antigen
L. Kasper (Hanover, US)
Vitamin D levels and MS features in progressive multiple sclerosis
D. Ontaneda (Cleveland, US)
Impact of smoking on treatment response in multiple sclerosis patients receiving disease
modifying therapies
J. Sequeira (Barcelona, ES)
Latent γHV-68 infection facilitates MS-like symptoms through memory B cells in EAE
A.C. Márquez (Vancouver, CA)
Synergistic effects of combined sodium chloride and saturated long chain fatty acid
challenge on differentiation of Th17 cells in neuroinflammation
A. Hammer (Erlangen, DE)
Fresh fish consumption is associated with a lower risk of multiple sclerosis independent of
serum 25OHD levels
Short-term exposure to ambient air pollution and occurrence of multiple sclerosis relapses
M. Jeanjean (Rennes, FR)
Different environmental stimuli may activate common biological processes potentially
involved in multiple sclerosis
R. Mechelli (Rome, IT)
Post-vaccination autoimmune CNS demyelination in a family with MOG antibodies - genes or
environment?
A.-K. Pröbstel (Basel, CH)
Salt-sensitive alterations in gut microbiota impact Th17 cells and neuroinflammation
S. Jörg (Erlangen, DE)
Comparison of humoral immunity against acid-fast bacilli lipophilic antigens in patients with
Japanese MS and NMOSD
K. Yokoyama (Tokyo, JP)
Smoking is associated with increased relapse rate in natalizumab-treated MS
E.R. Petersen (Copenhagen, DK)
Vaccines increase the risk of relapses in neuromyelitis optica spectrum disorder among
untreated patients
M.A. Mealy (Baltimore, US)
Page 33 / 108

Relevance of the microbiota during the autoimmune phase in a viral model of multiple
sclerosis
L. Mestre (Madrid, ES)
Smoking on disability accumulation in neuromyelitis optica and multiple sclerosis
S. Messina (Oxford, UK)
Rapid and efficient generation of human oligodendrocytes from induced pluripotent stem
cells to model demyelinating diseases
L. Starost (Münster, DE)
Interleukin 17 affects hippocampal plasticity and cognition in multiple sclerosis
M. Di Filippo (Perugia, IT)
Astrocytic Junctional Adhesion Molecule-A promotes CNS inflammatory lesion pathogenesis
C. Chapouly (New York, US)
Proteomic analysis of CNS-derived microvescicles in the cerebrospinal fluid of MS
M. Puthenparampil (Padua, IT)
MS as a transmissible protein misfolding disorder
S. Tsutsui (Calgary, CA)
CD320-vitamin B12 links to MS thru S1P1 signaling in activated astrocytes
J. Chun (La Jolla, US)
Demyelination controls epigenetic changes in multiple sclerosis hippocampus
R. Dutta (Cleveland, US)
Longitudinal follow up of optical coherence tomography determined MS phenotypes with
retinal and brain imaging
N. Gonzalez Caldito (Baltimore, US)
Serpina3n: potential biomarker in patients with progressive multiple sclerosis
N. Fissolo (Barcelona, ES)
VEGF in cerebrospinal fluid from patients with RRMS, PPMS and ALS
R. Dersch (Freiburg, DE)
Leptomeningeal contrast enhancement in multiple sclerosis is associated with grey matter
atrophy and higher disability
G. Makshakov (Saint-Petersburg, RU)
Human stem cell-based screen for small molecules that promote oligodendrocyte
differentiation, myelination, and neuronal survival
D.J. Zack (Baltimore, US)
Reconstruction of the pan-glial network during induced pluripotent stem cell-derived
remyelination process
S. Mozafari (Paris, FR)
Nodes of Ranvier reclustering can precede remyelination: a role in repair?
M. Thetiot (Paris, FR)
Page 34 / 108

Relationships between reorganization of functional brain network topology and cognition in
clinically isolated syndrome: a 1 year Resting-state fMRI longitudinal study
I. Koubiyr (Bordeaux, FR)
The severity of functional and structural brain pathology reflects information processing
speed deficits in multiple sclerosis
K.A. Meijer (Amsterdam, NL)
Cortical lesions and their correlates in multiple sclerosis: findings from a large cohort at 7T
C.A. Treaba (Charlestown, US)
Neuroinflammatory component of cerebellar pathology in multiple sclerosis by 11C-PBR28
MR-PET
V. Barletta (Boston, US)
Preferential spinal cord volume loss in primary progressive multiple sclerosis
C. Tsagkas (Basel, CH)
Dynamic functional network connectivity in CIS patients: a longitudinal study
M. Hidalgo de la Cruz (Milan, IT)
Impact of removing facial features from MR images of MS patients on automatic lesion and
atrophy metrics
A. de Sitter (Amsterdam, NL)
Impact of deep grey matter volume loss on neurological impairment in patients with
multiple sclerosis: a 6-year follow-up study with annual MRI
S. Magon (Basel, CH)
Whole brain magnetic resonance fingerprinting in multiple sclerosis
S. Llufriu (Barcelona, ES)
Longitudinal structural network reorganisation in early relapsing-remitting multiple
sclerosis
V. Fleischer (Mainz, DE)
Multiple sclerosis patients who improve in their disability over time develop less brain
atrophy compared to those who remain stable or progress
E. Ghione (Buffalo, US)
Predicting clinical progression in multiple sclerosis six and twelve years after onset
I. Dekker (Amsterdam, NL)
Improved visualization of cortical lesions in multiple sclerosis using MP2RAGE at 7T
E.S. Beck (Bethesda, US)
Lesions with hyperintense rim on quantitative susceptibility mapping demonstrate more
inflammation on PET-PK11195
U. Kaunzner (New York, US)
Pattern recognition for neuroimaging toolbox PRoNTo: a pilot study in predicting clinically
isolated syndrome conversion
D. Pareto (Barcelona, ES)
Page 35 / 108

Normative rates of healthy age-related brain volume changes as assessed by SIENA on a
large MRI dataset
M. Battaglini (Siena, IT)
Contrast enhanced susceptibility-weighted imaging of acute and chronic MS lesions
A. Gass (Mannheim, DE)
Within patient fluctuation of brain volume estimates from short-term repeated MRI
measurements using SIENA/FSL
R. Opfer (Hamburg, DE)
Quantitative MRI texture analysis of enhancing and non-enhancing T1-hypointense lesions
without application of contrast agent in multiple sclerosis
S.M. Nabavi (Tehran, IR)
Age-dependent cut-off for pathological brain volume loss measured with SIENA/FSL
R. Opfer (Hamburg, DE)
Associations between low conscientiousness and cognitive impairment in MS may be due to
shared pathophysiology: structural network disruption of frontal cortex regions
T. Fuchs (Buffalo, US)
Altered subcortical sensorimotor integration in multiple sclerosis: a combined
neurophysiological and MRI study
C. Giannì (Rome, IT)
Dynamic volumetric changes of hippocampal subfields in CIS patients: a 2-year MRI study
L. Cacciaguerra (Milan, IT)
Leptomeningeal enhancement on Gadolinium-enhanced 3D-FLAIR MRI in MS vs. non-MS
patients: demographic characteristics, and relationship to disease modifying therapy and
white matter disease activity
D.S. Titelbaum (Brockton, US)
Defining a minimal meaningful lesion size in multiple sclerosis
S. Grahl (Munich, DE)
Column-specific demyelination in spinal cord normal appearing white matter occurring in
multiple sclerosis: a preliminary study using inhomogeneous magnetization transfer and
diffusion tensor imaging
H. Rasoanandrianina (Marseille, FR)
MRI myelin water fraction provides evidence of long-term neuro-recovery in alemtuzumab
treated multiple sclerosis patients
I.M. Vavasour (Vancouver, CA)
Lesion-based disruption of connections between the amygdala and surrounding ipsilateral
structures may be protective against fatigue in multiple sclerosis
T. Fuchs (Buffalo, US)
Occurrence of diffusely abnormal white matter in individuals with clinically isolated
syndromes suggestive of multiple sclerosis
C. Laule (Vancouver, CA)
Page 36 / 108

Identification of new cortical lesions on longitudinal 7-Tesla MP2RAGE subtraction MRI in
multiple sclerosis
D. Harrison (Baltimore, US)
Application of Neurite Orientation Dispersion and Density Imaging (NODDI) in clinically
isolated syndrome (CIS)
S. Collorone (London, UK)
The impact of CNS inflammation on the GABAergic system: a multi-ligand PET study utilizing
[11C] flumazenil and [11C] PK11195
Y. Kang (New York, US)
Cortical mantle thinning in the visual cortex in pediatric-onset multiple sclerosis
R. Datta (Philadelphia, US)
Coordinate based random effect size meta-analysis shows regions of GM atrophy do not
develop independently in MS and CIS
C. Tench (Nottingham, UK)
Longitudinal study to measure iron deposit in basal ganglia and related structures in
patients with clinically isolated syndrome
Evolution of venous narrowing in acute MS lesions
A. Gass (Mannheim, DE)
Normative data of MRI-derived thalamic volumes from a large dataset of healthy subjects
G. Gentile (Siena, IT)
Spinal cord ring enhancement patterns in neuromyelitis optica spectrum disorder:
comparison with multiple sclerosis
Y.-M. Lim (Seoul, KR)
Myelin deterioration occurs in relapsing remitting multiple sclerosis patients meeting
criteria for “no evidence of disease activity”
A. Harel (New York, US)
Resting state fMRI and graph theory for the automatic classification of relapsing remitting
multiple sclerosis with different disease duration
G. Castellazzi (Pavia, IT)
3T FLAIR* MRI improve the differentiation between multiple sclerosis and CNS vasculitis
white matter lesions
P. Maggi (Bruxelles, BE)
Mapping neuroeconomic decisions in multiple sclerosis: a connectivity approach
S. Llufriu (Barcelona, ES)
Probing myelin and axonal integrity in multiple sclerosis brains
G. Franco (Nashville, US)
Comparative study of brain atrophy measures in CIS and MS patients: preliminary results of
a cross-sectional analysis
S. Cappelle (Barcelona, ES)
Page 37 / 108

Altered cerebellar functional connectivity is associated to clinical disability in multiple
sclerosis
S. Tommasin (Rome, IT)
Independent component analysis of cerebral blood flow reveals MS-specific spatial patterns
associated with clinical disability
N. Bergsland (Buffalo, US)
Microstructural alterations precede subcortical deep grey matter volume loss in patients
with clinically isolated syndrome
I. Koubiyr (Bordeaux, FR)
Characterization of spinal cord pathology and its correlates at ultra-high field MRI
R. Ouellette (Charlestown, US)
Distinct associations of cross-sectional spinal cord areas with clinical disability in Japanese
patients with multiple sclerosis and neuromyelitis optica spectrum disorder with
aquaporin-4-IgG
Y. Nakamura (Fukuoka, JP)
Regional patterns of brain atrophy development in pediatric and adult multiple sclerosis
patients: a 3.5 year study
E. De Meo (Milan, IT)
Regional brain atrophy differences and relationship to disability in NMOSD and MS
E. Russell (Vancouver, CA)
Longitudinal characterization of MRI phenotypes based on cerebral lesions and atrophy in
multiple sclerosis: a five year study
C. Hemond (Boston, US)
A semi-automatic method to segment multiple sclerosis lesions on FLAIR magnetic
resonance images
L. Storelli (Milan, IT)
Trans-synaptic neurodegeneration 12 months following optic neuritis - a longitudinal OCT
and DTI study
J.B. McKee (Headington, UK)
Characterization of the haemodynamic response function in multiple sclerosis
A.A. Alahmadi (London, UK)
Metabolic substrates of efficiency reduction in the frontoparietal network in multiple
sclerosis
E. Solana (Barcelona, ES)
Reduced dynamism of functional connectivity is associated with cognitive impairment in MS
patients: a dynamic functional connectivity study in a multi-center setting
A. d'Ambrosio (Milan, IT)
Do multiple sclerosis lesions affect automatic brain structure segmentation?
X. Llado (Girona, ES)
Page 38 / 108

Presence of focal and diffuse cervical cord tissue damage in early relapsing-remitting MS: a
magnetization transfer study
A. Kerbrat (Rennes, FR)
Accelerated thalamic atrophy occurs following acute optic neuritis
E.S. Sotirchos (Baltimore, US)
The relationship between network measures and magnetic resonance imaging metrics in
multiple sclerosis
T. Charalambous (London, UK)
Automated detection of central vein sign in white matter lesions for the diagnosis of MS
J.D. Dworkin (Philadelphia, US)
Statistical separation of spatially confluent but temporally distinct white matter lesions
J.D. Dworkin (Philadelphia, US)
Shrinking of T2-hyperintense white matter lesions in early multiple sclerosis
V. Biberacher (München, DE)
Evidence for progressive neurodegeneration in the cervical cord of patients with early
primary progressive MS during 3-year follow-up
R. Cortese (London, UK)
Cervical spinal cord volume and diffuse spinal cord abnormalities distinguish multiple
sclerosis patients with different levels of disability already 5 years after disease onset
M. Andelova (Prague, CZ)
Structure and function of the corticospinal tract and motor cortex in multiple sclerosis
J.Y. Garber (Sydney, AU)
Individual profiles of microglial activation drive the progression of clinical disability in MS
B. Bodini (Paris, FR)
Phase 1 safety study of ferumoxytol, an ultrasmall superparamagnetic iron oxide
nanoparticle, in multiple sclerosis and healthy volunteers at 7-tesla
M.K. Schindler (Bethesda, US)
Sources of variability in brain atrophy measurements in individual MS patients
A. Tsang (Cambridge, US)
Automated, modular MRI processing for multiple sclerosis using the BRAINMAP framework
B.E. Dewey (Baltimore, US)
Grey matter connectivity in clinically isolated syndromes
D. Pareto (Barcelona, ES)
Improving the accuracy of brain tissue loss assessment in patients with multiple sclerosis: a
role for diffusion imaging?
C. Wang (Sydney, AU)
Investigating resting-state BOLD variability in early multiple sclerosis
G. Bommarito (Genoa, IT)
Page 39 / 108

Validation of fully automated machine-learning algorithm for T2 lesion segmentation from
clinical MRI in multiple sclerosis
J.J. Feng (Cleveland, US)
Comparison between the 2010 McDonald and 2016 MAGNIMS MRI criteria for dissemination
in space in patients with a clinically isolated syndrome. Does the recent recommendation
regarding the current criteria improve diagnostic accuracy?
R. Lamas Pérez (Sevilla, ES)
Increased between-network functional connectivity as a compensatory mechanism to
maintain walking ability in MS patients
S. Ruggieri (Rome, IT)
Larger maximal lifetime brain growth is associated with faster motor speed in early
relapsing multiple sclerosis
C. Riley (New York, US)
Dark rims around white matter lesions using Gray-Matter Double-Inversion-Recovery MRI: A
novel specific imaging marker for multiple sclerosis
J.-M. Tillema (Rochester, US)
Structural MRI correlates of hand motor performance in patients with multiple sclerosis
C. Cordani (Milan, IT)
Retinal inner nuclear layer volume: a potential new outcome measure for optic neuritis
treatment trials in MS
L.J. Balk (Amsterdam, NL)
Visual evoked potentials are more sensitive than optical coherence tomography in clinically
isolated syndrome
Silent retinal atrophy in multiple sclerosis is mainly due to silent optic nerve lesions
O. Outteryck (Lille, FR)
Association of retinal layer architecture and the development of neuropsychological deficits
in early multiple sclerosis
C. Wetzlmair (Munich, DE)
A multidisciplinary assessment through OCT and correlations to brain pathology and
endothelial factors in multiple sclerosis
R. Lanzillo (Naples, IT)
Examining cross-sectional relationships of optical coherence tomography, cervical cord MRI
and disability in secondary progressive MS
F. De Angelis (London, UK)
Retinal changes in aquaporin-4 antibody seropositive neuromyelitis optica spectrum
disorders: a longitudinal study
F.C. Oertel (Berlin, DE)
Spectrum of stiff person syndrome expands with presence of retinal pathology
T. Shoemaker (Baltimore, US)
Page 40 / 108

Retinal ganglion cell layer thickness predicts disease activity in clinically isolated syndrome
H.G. Zimmermann (Berlin, DE)
Optical coherence tomography as a marker of disease severity and disability in pediatric
multiple sclerosis
N.M. Shukla (Houston, US)
An investigation into the relationship between Optical Coherence Tomography (OCT) and
cognitive fatigue in people with multiple sclerosis
M. Gudesblatt (Patchogue, US)
Cognitive impairment as prognostic factor in pediatric and juvenile multiple sclerosis
R. Lanzillo (Naples, IT)
Neurophysiological measures of fatigue in multiple sclerosis
S.S. Ayache (Créteil, FR)
The triple stimulation technique: a potential surrogate marker for motor axonal loss in
multiple sclerosis
X. Giffroy (Esneux, BE)
Fatigue in multiple sclerosis:Is it related to cytokines and hypothalamic-puituitary-adrenal
axis?
A. Akcali (Gaziantep, TR)
Cognitive impairment in multiple sclerosis is associated with slowing of resting state
oscillatory activity on magnetoencephalography
E.M. Strijbis (Amsterdam, NL)
Chronic 4-aminopyridine treatment enhances intracortical glutamatergic transmission in
S. Gelibter (Milan, IT)
Are we underestimating the severity of cognitive dysfunction in MS?
M. Weber (Cleveland, US)
Gray matter atrophy and microstructural white matter abnormalities underlying cognitive
impairment in benign MS
M.A. Rocca (Milan, IT)
Cognitive impairment in multiple sclerosis: the contribution of cognitive reserve and
regional gray matter volumes
A. Bisecco (Napoli, IT)
Neuroticism is linked to smaller hippocampal volume and worse memory in early multiple
sclerosis
V.M. Leavitt (New York, US)
Dissociable neural correlates of speed and memory in early multiple sclerosis: a latent
variable approach
J.F. Sumowski (New York, US)
Evolution of cognitive function in MS and its relationship to physical disability and MRI
metrics
D. Pinter (Graz, AT)
Page 41 / 108

Basal ganglia structural and functional abnormalities in multiple sclerosis are related to
cognitive impairment
Á.J. Cruz-Gómez (Castellón de la Plana, ES)
Cognitive status of patients with multiple sclerosis is associated to cognitive reserve better
than conventional MRI measures
A. Gallo (Naples, IT)
Intensive neurorehabilitation is associated with improved fatigue and depression in
patients with progressive MS
M. Congiu (Milan, IT)
Specific rehabilitation improves information processing speed and attention in MS: a
randomized trial against non-specific training with semi-ecological evaluation
D. Lamargue-Hamel (Bordeaux, FR)
Problem solving in patients with multiple sclerosis - analysing information and optimising
strategies under different conditions
K. Zebenholzer (Vienna, AT)
The symbol digit modalities test and the frontal systems behaviour scale: a one-year follow-
up study
L. Querol (Barcelona, ES)
Neuropsychological and anatomical correlates of theory of mind in patients with multiple
sclerosis
M.A. Chalah (Créteil, FR)
Evidence for flattened emotional experience in patients with clinically isolated syndrome
and early multiple sclerosis
Cerebrospinal fluid neurofilament light chain is a marker of disease activity in multiple
sclerosis
E. Poletto (Verona, IT)
Autoantibodies to neurofilament light protein as a potential biomarker of treatment
response and disease progression in multiple sclerosis
F. Puentes (London, UK)
Differential gene expression in stable and active MS patients treated with fingolimod
H. Bach Søndergaard (Copenhagen, DK)
Anticipation of long-term disability progression in PPMS using MRI: a 15-year longitudinal
study
M.A. Rocca (Milan, IT)
Serum neurofilament light levels at the time of a clinically isolated syndrome are associated
with long-term clinical and radiological outcome
T. Plavina (Cambridge, US)
High neurofilament light chain levels in CSF are associated with CDMS diagnosis in children
and adults with CIS
R.M. van der Vuurst de Vries (Rotterdam, NL)
Page 42 / 108

Serum glial fibrillary acidic protein correlates with disease severity and neuroaxonal demise
in multiple sclerosis: a pilot study using Simoa technology
A. Abdelhak (Ulm, DE)
Relationship between different cerebrospinal fluid biomarkers in multiple sclerosis:
meaning and use in clinical practice
B. Casanova (València, ES)
Lower baseline levels of vitamin D are associated with a higher risk of new lesion
development in patients with relapsing multiple sclerosis
G.J. Opiteck (San Diego, US)
Neuroinflammation and neuroaxonal damage in multiple sclerosis: a cross-sectional
cerebrospinal fluid-based proteomic study
L. Gaetani (Perugia, IT)
Neurofilament light chain in CSF and serum in relation to disease activity and brain volume
loss during four years of follow-up in a cohort of patients with CIS and RRMS
I. Håkansson (Linköping, SE)
Serum neurofilament light chain correlates with disease activity and predicts clinical and
MRI outcomes in MS
C. Barro (Basel, CH)
Neurofilament light chain in human blood is a predictor of disease worsening in relapsing-
remitting multiple sclerosis
J. Kuhle (Basel, CH)
Intrathecal B-cell inflammation influences CSF macrophage activity and the degree of
cortical pathology in multiple sclerosis
R. Magliozzi (Verona, IT)
MS treatment effects on plasma cytokine receptor levels
S.K. Bedri (Stockholm, SE)
Serum neurofilament light chain as a biomarker for acute and chronic neuronal damage in
early relapsing-remitting multiple sclerosis
N. Siller (Mainz, DE)
Baseline cerebellar volume predicts subsequent clinical disability in multiple sclerosis: MRI
findings from the CombiRx trial
M. Petracca (New York, US)
Serum exosomes expression of myelin proteins is a biomarker of the multiple sclerosis
activity
M.P. Mycko (Lodz, PL)
Intrathecal immunoglobulin synthesis as a predictive marker for disability progression in
multiple sclerosis
C. Gasperi (Munich, DE)
Decreased cerebrospinal fluid antioxidative capacity is associated with disease severity and
progression in early multiple sclerosis
M.M. Voortman (Graz, AT)
Page 43 / 108

Change of olfactory function as a marker of inflammatory activity and disability progression
in MS
G. Bsteh (Innsbruck, AT)
Multiple sclerosis: structure-function correlations in the cerebral cortex
H. Beadnall (Sydney, AU)
Conduction velocity in demyelinated cerebral white matter: a structure-function correlation
study in optic radiation
C. Wang (Sydney, AU)
Elucidation of pro-resolving lipid mediators in the cerebrospinal fluid: implications for
multiple sclerosis pathogenesis
G. Kooij (Amsterdam, NL)
Single-cell mRNA marker analysis reveals appearance of t-SNE-defined new B-cell clusters in
cynomolgus monkeys in response to ofatumumab treatment
P. Couttet (Basel, CH)
The neutrophil-to-lymphocyte ratio is associated with multiple sclerosis
I.C. Hasselbalch (Copenhagen, DK)
Delayed-release dimethyl fumarate demonstrated no evidence of difference in clinical
outcomes vs fingolimod in patients with RRMS: a propensity-matched comparative
effectiveness analysis of the German NeuroTransData registry
S. Braune (Prien, DE)
Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell
transplantation. The Italian experience
G. Boffa (Genova, IT)
Naturally or induced immunization against CCL20 confer protection against experimental
A. Karni (Tel Aviv, IL)
Ocrelizumab reduces disability progression independent of relapse activity in patients with
relapsing multiple sclerosis
Long-term lymphocyte counts in patients with relapsing-remitting multiple sclerosis (RRMS)
treated with cladribine tablets 3.5 mg/kg: total lymphocytes, B and T cell subsets
P. Soelberg Sorensen (Copenhagen, DK)
Characterization of the efficacy of ORY-2001, a novel epigenetic drug for the treatment of
multiple sclerosis, during the effector phase of the EAE model
T. Maes (Cornella de Ll., ES)
Subcutaneous low dose ofatumumab in cynomolgus monkeys induced changes in
lymphocyte subsets and reversible cytoarchitectural changes in lymph nodes
D. Theil (Basel, CH)
Rescue therapy with propionic acid reverts the pro-inflammatory effects of a high-fat-diet in
neuroinflammation
J. Mäurer (Erlangen, DE)
Page 44 / 108

Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small
subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy
interferon beta-1a-controlled study
H.-C. von Buedingen (Basel, CH)
Dimethyl fumarate reduces the frequency of antigen-experienced B cells in patients with
multiple sclerosis
R.H. Hansen (Copenhagen, DK)
Efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-
remitting multiple sclerosis: eight-year follow-up of an integrated analysis of DEFINE,
CONFIRM, and ENDORSE
R. Gold (Bochum, DE)
Peginterferon beta-1a improves clinical and radiological disease outcomes in patients who
are newly diagnosed with relapsing multiple sclerosis: subgroup analysis of ADVANCE
S.D. Newsome (Baltimore, US)
Comparative effectiveness and discontinuation of dimethyl fumarate and fingolimod in two
large academic medical centers at 24-month follow-up
C.M. Hersh (Las Vegas, US)
Real life use of natalizumab and fingolimod - data from the nation-wide Austrian Multiple
Sclerosis Treatment Registry
M. Guger (Linz, AT)
Dimethyl fumarate vs. fingolimod in multiple sclerosis: an independent, multi-centre, real
world, quasi-randomized study
L. Prosperini (Rome, IT)
Rates of lymphopenia year-by-year in patients with relapsing multiple sclerosis treated and
retreated with cladribine tablets 3.5mg/kg
S. Cook (Newark, US)
Effects of cladribine tablets on CD4+ T cell subsets in the ORACLE-MS study: results from an
analysis of lymphocyte surface markers
O. Stuve (Dallas, US)
T-cell population changes and serious infection rates in the controlled periods of the pivotal
phase III trials of ocrelizumab in multiple sclerosis
P. Vermersch (Lille, FR)
Two years real life safety, tolerability and efficacy of dimethyl fumarate in an Italian
multicentre study
G. Mallucci (Pavia, IT)
Rituximab real life efficacy in MS: an observational multicentre study
S. Malucchi (Orbassano, IT)
Slowing of cortical grey matter atrophy with teriflunomide is associated with delayed
conversion to clinically definite MS
R. Zivadinov (Buffalo, US)
Confirmed disability improvement in patients treated with fingolimod in phase 3 and
extension trial programmes for up to 96 months
Page 45 / 108

Comparison of rituximab and highly effective second line disease modifying therapies after
breakthrough disease activity in relapsing-remitting multiple sclerosis
J. Salzer (Umeå, SE)
Relapse rates and disability in the modern treatment era of neuromyelitis optica: data from
a specialist UK centre
D.H. Whittam (Liverpool, UK)
Design of a phase II dose range finding, efficacy and safety study of the Bruton's tyrosine
kinase inhibitor evobrutinib (M2951) in relapsing multiple sclerosis patients
Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and
primary progressive multiple sclerosis
Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting
multiple sclerosis: a comparative longitudinal study
T cell mediated experimental CNS autoimmunity induced by PLP in SJL mice is modulated by
Evobrutinib (M2951) a novel Bruton's tyrosine kinase inhibitor
U. Boschert (Billerica, US)
Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple
sclerosis
C. Boz (Trabzon, TR)
Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in relapsing-
remitting multiple sclerosis in clinical practice at 24-month follow-up
C.M. Hersh (Las Vegas, US)
An observational study of alemtuzumab-treated relapsing MS patients at the UBC MS Clinic
H.Y. Yong (Vancouver, CA)
Safety, tolerability, and pharmacodynamics of intravenous and subcutaneous doses of the
anti-CD52 antibody GLD52 in patients with progressive MS: a randomised, controlled, single
ascending dose trial
D.H. Margolin (Cambridge, US)
Dimethyl fumarate therapy is associated with immune-deviation and anti-inflammatory
cytokine profiles in B and T cells in patients with multiple sclerosis
E. Najjar (Haifa, IL)
Changing disease modifying therapy switching dynamics for relapsing-remitting multiple
sclerosis patients
C. Wakeford (Cambridge, US)
Evaluation of the long-term treatment effect of teriflunomide on cognitive outcomes and
association with brain volume change: data from TEMSO and its extension study
T. Sprenger (Basel, CH)
Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and
epidemiological studies
Page 46 / 108

Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis
who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II
studies
C. Papeix (Paris, FR)
Subgroup analyses of no evidence of disease activity in patients with relapsing multiple
sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and
OPERA II studies
B. Turner (London, UK)
Efficacy and safety of alemtuzumab versus fingolimod in RRMS patients after switch from
natalizumab: a retrospective analysis
S. Pfeuffer (Münster, DE)
Cladribine tablets produce selective and discontinuous reduction of B and T lymphocytes
and natural killer cells in patients with early and relapsing multiple sclerosis (ORACLE-MS,
CLARITY and CLARITY Extension)
O. Stuve (Dallas, US)
A central role of B cells in MS control and causing autoimmunity after alemtuzumab
D. Baker (London, UK)
Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and
their ability to activate T cells
M.A. Mazzola (Boston, US)
Effect of ocrelizumab on B and T cell immune repertoires in patients with relapsing multiple
sclerosis
S. Laurent (San Francisco, US)
The immune receptor expression pattern in peripheral-blood associated with JCV
seropositivity in patients with multiple sclerosis is not affected by natalizumab
A. Harrer (Salzburg, AT)
Achievement of no evidence of disease activity with daclizumab beta versus intramuscular
interferon beta-1a treatment across patient subgroups in DECIDE
Immunosuppressive potential of human Wharton jelly mesenchymal stem cells in multiple
sclerosis patients
M. Swiderek-Matysiak (Lodz, PL)
“Real-life” outcomes in a monocentric cohort of highly active multiple sclerosis patients
treated with alemtuzumab
L. Moiola (Milan, IT)
Efficacy and safety of generic glatiramer acetate Timexon®: results of the 12-month
extension of BCD-063-1 international double-blind randomized placebo-controlled clinical
study of efficacy and safety of Timexon® in comparison with Copaxone®
C. Tursunova (Saint-Petersburg, RU)
Secukinumab in relapsing multiple sclerosis: experience in two cases with concomitant
ankylosing spondylitis
R. Robles Cedeño (Girona, ES)
Page 47 / 108

A cost-effectiveness analysis using real-world data from the MSBase Registry: comparing
natalizumab to fingolimod in patients with inadequate response to disease modifying
therapies in relapsing-remitting multiple sclerosis in Scotland
C. Acosta (Zug, CH)
Teriflunomide: immunomodulatory effect on adaptive and innate immune cell subsets
I. Gandoglia (Genoa, IT)
Fingolimod induces BAFF and expands circulating transitional B cells without activating
memory B cells and plasma cells in multiple sclerosis
Y. Miyazaki (Sapporo, JP)
Induction of disease remission with one cycle of alemtuzumab in relapsing remitting
multiple sclerosis
D.E. Klein (Middletown, US)
Real-life experience with rituximab for the treatment of multiple sclerosis: report from two
MS referral centres
F.C. Pérez Miralles (Valencia, ES)
Ozanimod does not impact cytotoxic T lymphocyte function in vitro demonstrating
differentiation from fingolimod's activity on SET-PP2A
D. Guimond (San Diego, US)
In vitro data reveals potential novel mechanism of action of teriflunomide on CNS microglia
and astrocytes
A. Edling (Framingham, US)
Teriflunomide use in European clinical practice in patients with relapsing forms of multiple
sclerosis: an overview of regional real-world studies
A. Chan (Bern, CH)
EVOLVE-MS-2: A randomized, double-blind, phase 3 study of the gastrointestinal tolerability
of ALKS 8700 versus dimethyl fumarate in relapsing-remitting multiple sclerosis
R.T. Naismith (Saint Louis, US)
Spanish registry of patients with multiple sclerosis treated with fingolimod (GILENYA
Registry): safety and effectiveness after four years of registry
J. Meca-Lallana (Murcia, ES)
An update on pregnancy outcomes following ocrelizumab treatment in patients with
multiple sclerosis and other autoimmune diseases
S. Vukusic (Lyon, FR)
Sustained modifications of subsets and capacities of cytokine production of B cells under
interferon-β in multiple sclerosis
T. Guerrier (Lille, FR)
Rituximab in multiple sclerosis, frequency and clinical relevance of anti-rituximab drug
antibodies
A. Juto (Stockholm, SE)
Once daily oral CHS-131, a novel PPARγ agonist, reduces both neuroinflammation and gray
matter volume depletion in patients with relapsing-remitting multiple sclerosis: a
randomized, placebo controlled double-blind, Phase 2b, multicenter study
D. Weinstein (Redwood City, US)
Page 48 / 108

Investigating neuroprotective effects of phenytoin on optic nerve magnetization transfer
ratio (MTR) in acute optic neuritis
A.T. Toosy (London, UK)
Dimethyl fumarate (DMF) improves behavioral outcomes in a mouse model of progressive
multiple sclerosis
B. Bai (Cleveland, US)
Patterns of regional gray matter and white matter atrophy in patients starting fingolimod or
natalizumab: a 2-year tensor-based morphometry study
P. Preziosa (Milan, IT)
Blocking LINGO family promotes axon regeneration in the optic nerve crush model
S. Mi (Cambridge, US)
Predictors of an opicinumab treatment effect and identification of an efficacy
subpopulation: a post hoc analysis of the SYNERGY study
S. Sheikh (Cambridge, US)
Keeping mitochondria on the road: teriflunomide maintains mitochondrial motility levels in
axons challenged with oxidative stress
E. Bros (Berlin, DE)
Selective estrogen receptor modulators significantly enhance remyelination in an estrogen
receptor-independent manner
Phase I/II clinical trials testing multiple dosing of intrathecal mesenchymal stem cell-
derived neural progenitors in patients with progressive multiple sclerosis
S.A. Sadiq (New York, US)
Fingolimod-mediated axonal protection during demyelination facilitates myelin increase
during recovery
B. Bai (Cleveland, US)
Protection of mitochondrial function by dimethyl fumarate in an animal model of multiple
sclerosis
D. Schiza (London, UK)
Alemtuzumab reduced MRI lesions and slowed brain volume loss in CARE-MS II patients
switching from SC IFNB-1a: 5-year follow-up after alemtuzumab (TOPAZ study)
D. Pelletier (Los Angeles, US)
Predictors of relapses and disability progression after stopping disease-modifying therapies
for multiple sclerosis
I. Kister (New York, US)
Alemtuzumab after Natalizumab SWitch in Evolving Rapidly Severe Multiple Sclerosis
(ANSWERS MS)
P.J. Gallagher (Glasgow, UK)
Efficacy of a third course of alemtuzumab in patients with active relapsing-remitting
multiple sclerosis who experienced disease activity after the initial two courses: pooled
analysis of CARE-MS I and II
Page 49 / 108

Alemtuzumab decreased MRI disease activity and slowed brain volume loss over 5 years
after switching from SC IFNB-1a: follow-up of CARE-MS I (TOPAZ study)
Effectiveness, health outcomes and cost-effectiveness of first generation disease-modifying
drugs in relapsing-onset multiple sclerosis: Nova Scotia evidence 1979-2010
M.G. Brown (Halifax, CA)
Sustained efficacy of daclizumab beta over up to 6 years of treatment and improvements in
efficacy outcomes in relapsing MS patients who switched from intramuscular interferon
beta-1a to daclizumab beta: interim results from EXTEND
Disease modifying therapy improves disability outcomes in relapsing-remitting multiple
sclerosis over 22 years
Clinical outcomes were better for patients who remained on natalizumab compared to those
who switched to oral or injectable therapies after 2 years in the TYSABRI Observational
Program
Less frequent retreatment of rituximab is sufficient to maintain remission of neuromyelitis
optica spectrum disorder after long-term treatment of rituximab
H.J. Kim (Goyang, KR)
A Swedish nationwide pharmaco-epidemiological study of the long-term safety and
effectiveness of natalizumab (IMSE 1)
S. Kågström (Stockholm, SE)
Durable improvements in clinical outcomes with alemtuzumab in patients with active RRMS
in the absence of continuous treatment: 7-year follow-up of CARE-MS II patients (TOPAZ
study)
B. Singer (St. Louis, US)
Lateral ventricular volume as a proxy for brain volume loss in the assessment of no
evidence of disease activity: results from a longitudinal, multicentre, real-world study
R. Zivadinov (Buffalo, US)
Big Multiple Sclerosis Data network: data sharing among five large MS registries
P. Iaffaldano (Bari, IT)
Serum neurofilament light chain levels are increased at the onset of PML in natalizumab
treated MS patients
G. Dalla Costa (Milan, IT)
Improved precision of automatic brain volume measurements in patients with clinically
isolated syndrome and multiple sclerosis using edema correction
M. Warntjes (Linköping, SE)
Patients with active RRMS experience durable reductions in MRI disease activity and
slowing of brain volume loss with alemtuzumab: 7-year follow-up of CARE-MS II patients
(TOPAZ study)
D. Pelletier (Los Angeles, US)
Page 50 / 108

Effect of teriflunomide on lymphocyte counts and infections over the long-term in the
pooled TEMSO and TOWER extension studies
G. Comi (Milan, IT)
Lymphocyte decline and reconstitution after discontinuation in patients with severe,
prolonged lymphopenia treated with delayed-release dimethyl fumarate
Outcomes of discontinuing disease modifying therapy in patients with multiple sclerosis
over age 60
L.H. Hua (Las Vegas, US)
5 years effectiveness of fingolimod in daily clinical practice: results of the non-
interventional study PANGAEA
C. Cornelissen (Nürnberg, DE)
Characteristics of real-world disability improvement in relapsing-remitting multiple
sclerosis patients treated with natalizumab in the TYSABRI® Observational Program
H. Wiendl (Münster, DE)
Comparative effectiveness of first line treatment strategies for multiple sclerosis
M. Granqvist (Solna, SE)
A Swedish nationwide pharmaco-epidemiological study of the long-term safety and
effectiveness of fingolimod (IMSE 2)
Å. Leandersson (Stockholm, SE)
Pregnancy outcomes in patients with RRMS treated with alemtuzumab from the clinical
development program
D. Rog (Manchester, UK)
Breakthrough disease under high-dose biotin treatment in progressive multiple sclerosis
F. Granella (Parma, IT)
The ultrasensitive JCV DNA Tri-Plex qPCR* detects JCV specific genomic sequences in T
protein, distinguishes pathogenic from non-pathogenic variants using the NCCR (Non-
Coding Control Region) and identifies the virion capsid protein gene (VP1)
E.O. Major (Besthesda, US)
Pregnancy planning and outcome in MS patients after Mitoxantrone therapy
J. Frau (Cagliari, IT)
Does IgG level impact JC virus index value?
H. Zéphir (Lille, FR)
Cardiac safety of ozanimod in a QT/QTc trial and a phase 2 trial in RMS
G. Comi (Milan, IT)
Patient initiation of fingolimod treatment: comparison of cardiac monitoring in-clinic and in
the Gilenya@Home program
J. Osborne (Grapevine, US)
Point of no return: outcomes from acute relapses of neuromyelitis optica depend on
severity
M. Levy (Baltimore, US)
Page 51 / 108

First reported case of aquired hemophilia A (AHA) as secondary autoimmune disease
following alemtuzumab treatment in multiple sclerosis
L. Moiola (Milan, IT)
Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab
discontinuation in patients with multiple sclerosis?
J. Krämer (Münster, DE)
Safety of alemtuzumab for multiple sclerosis after exposure to chemotherapeutic agents for
patients with multiple sclerosis - experience of a single MS center
D.A. Pimentel Maldonado (Worcester, US)
How best to communicate clinical trial information about DMD risks and benefits to MS
patients?
G. Reen (Egham, UK)
Alopecia totalis following alemtuzumab treatment in relapsing-remitting multiple sclerosis
J. Zimmermann (Bonn, DE)
Third Japanese case of fingolimod-associated PML in natalizumab-naïve MS: coincidence or
alarm bell?
J. Nakahara (Tokyo, JP)
Ozanimod has an improved nonclinical safety profile relative to fingolimod
S. Meier-Davis (San Diego, US)
First dose effects of fingolimod: final results of an in-depth ECG and Holter study in 6,998
German RRMS patients
V. Limmroth (Köln, DE)
Pregnancy outcomes in patients with multiple sclerosis and exposure to branded glatiramer
acetate during all three trimesters
O. Neudorfer (Petach Tikva, IL)
Characterizing the cytokine profile before and after antiCD20 infusions: c comparison of
rituximab versus ocrelizumab
E. Alvarez (Aurora, US)
Evaluation of a protocol to improve DMD risk and benefit understanding in MS patients: a
randomised crossover trial
G. Reen (Egham, UK)
An application of a novel statistical approach to predict patient-specific treatment
responses to DMTs based on a continuous score
F. Bovis (Genova, IT)
Minimal or no evidence of disease activity: which target to prevent long-term disability in
multiple sclerosis?
L. Prosperini (Rome, IT)
Disease activity as assessed by the MAGNIMS Score predicts long-term clinical disease
activity free status and disability progression in patients treated with subcutaneous
interferon beta-1a
M.P. Sormani (Genoa, IT)
Page 52 / 108

Defining areas of cognitive impairment in relapsing-remitting multiple sclerosis (RRMS) -
baseline analysis of a longitudinal multicenter study in 15 German practice centers
M. Stumpfe (Berg, DE)
Long-term disease outcomes in multiple sclerosis patients categorised by baseline brain
volume and with no disease activity over 2 years
M.H. Barnett (Sydney, AU)
Comparison between central and whole brain atrophy in multiple sclerosis measured by
structural image evaluation using normalization of atrophy (SIENA)
T. Sinnecker (Basel, CH)
Association of brain volume loss and NEDA outcomes in patients with relapsing multiple
sclerosis in the OPERA I and OPERA II studies
Permeability of the blood-brain barrier predicts no evidence of disease activity at two years
after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis
S.P. Cramer (Glostrup, DK)
Patient reported disease modifying therapy adherence in the clinic: a reliable metric?
D.S. Conway (Cleveland, US)
Overall response score: a novel disability endpoint that allows for the integrated
assessment of improvement and worsening over time in patients with MS
I. Chang (Cambridge, US)
The effect of dimethyl fumarate treatment on hippocampal metabolite levels in RRMS using
1H-MR spectroscopy
K.A. Ribbons (New Lambton, AU)
Silent lesions on MRI - shifting goal post for treatment decisions in MS
M. Min (Newcastle, AU)
Consensus statement on the use of gadolinium for magnetic resonance imaging used in the
diagnosis and follow-up of patients with multiple sclerosis
A comparative-effectiveness analysis applying a 3 way propensity matching to real-world
data from MSBase Registry in preparation for a cost effectiveness model: patients switching
within firstline agents or to natalizumab or fingolimod in active RRMS
Efficacy of siponimod on disability progression in SPMS patients with and without on-study
relapses
Anti-inflammatory disease modifying treatment and disability progression in primary
J. Lorscheider (Melbourne, AU)
Contribution of inflammation to disability accrual in primary progressive multiple sclerosis
Page 53 / 108

Safety and clinical improvement in a phase I trial of autologous Epstein-Barr virus-specific T-
cell therapy in patients with progressive multiple sclerosis
M.P. Pender (Brisbane, AU)
Effect of MD1003 (High-Dose Biotin) for the treatment of progressive MS: 36-month follow-
up data
A. Tourbah (Reims, FR)
Effect of MD1003 (High-Dose Biotin) in spinal progressive multiple sclerosis (MS-SPI):
subgroup analyses
A. Tourbah (Reims, FR)
A multicentre, randomized, double-blind, non-inferiority clinical trial to compare the clinical
and radiological efficacy of 625 mg versus 1250 mg of oral methylprednisolone in patients
with relapse of multiple sclerosis: the Oral-CORTEM trial
C. Ramo-Tello (Badalona, ES)
MS FIRST - utilising a longitudinal, prospective, comparative drug safety module for use in
everyday MS clinical practice to evaluate and track incidence and characteristics of safety
outcomes in MS patients on therapy over the long term
J. Haartsen (Melbourne, AU)
Effect of early switch to fingolimod from other oral therapies in patients with relapsing-
remitting multiple sclerosis
The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting
multiple sclerosis: results from REVEAL, a randomised, head-to-head phase 4 study
Probiotic VSL3 induces changes in the gut microbiome function and promotes an anti-
inflammatory peripheral immune response in multiple sclerosis patients
S. Tankou (Boston, US)
Patient characteristics, safety, and preliminary results of a placebo controlled, phase 2a
multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal
antibody (mAb), in patients with relapsing forms of multiple sclerosis
E.J. Fox (Round Rock, US)
Variability in adverse event reporting and reasons for discontinuations with dimethyl
fumarate: results from a generalized linear mixed model
F. Pellegrini (Zug, CH)
Overcoming therapeutic inertia in multiple sclerosis care: a pilot randomized trial
evaluating an educational intervention
G. Saposnik (Toronto, CA)
Siponimod pharmacokinetics, safety and tolerability in combination with the CYP2C9/3A4
inducer, rifampin in healthy subjects
A. Gardin (Basel, CH)
No evidence of disease activity status among patients with relapsing-remitting multiple
sclerosis on long-term natalizumab treatment: data from a real-world cohort in the Czech
Republic
Page 54 / 108

Ectrims actrims

Recommended

Recommended

More Related Content

Similar to Ectrims actrims

Similar to Ectrims actrims (20)

More from BartsMSBlog

More from BartsMSBlog (20)

Recently uploaded

Recently uploaded (20)

Ectrims actrims